NDA 050778 · Pfizer INC
Ellence
Epirubicin Hydrochloride · Injection
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Sep 15, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
608
204 Phase 3, 77 recruiting
FAERS reports
6,498
6,286 serious, 478 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIAC TOXICITY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION • Cardiac Toxicity: Myocardial damage, including acute left ventricular failure, can occur with ELLENCE. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 0.9% at a cumulative dose of 550 mg/m 2 , 1.6% at 700 mg/m 2 , and 3.3% at 900 mg/m 2 . The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with ELLENCE [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including ELLENCE [see Warnings and Precautions (5.2) ] . • Extravasation and Tissue...
What it is approved for
From the label in effect Jul 24, 2026.
ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] . ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).
Mechanism: Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 2, 2005 Supplement 8 · Efficacy LabelLetter
- Sep 15, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
2 products under this application
- ELLENCE · EPIRUBICIN HYDROCHLORIDE 200MG/100ML (2MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- ELLENCE · EPIRUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Epirubicin" as an intervention, any sponsor and status, largest first.
- ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT01779206 · 4,936 participants (planned) · Start May 2012 · Primary completion Sep 2019
Drug: Epirubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Munich, Germany; Mönchengladbach, Germany
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryPivotal-lookingStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00301925 · 4,400 participants (planned) · Start Dec 16, 2005 · Primary completion Sep 2024
Drug: pegfilgrastim; capecitabine and 4 more · For: Breast Cancer
Sites: Ashford-Kent, United Kingdom; Ashington, United Kingdom; Ashton-under-Lyne, United Kingdom · 152 sites in all
- 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer PatientsPivotal-lookingStatus unknown
Martin-Luther-Universität Halle-WittenbergAcademic, hospital or other
NCT01222052 · 4,150 participants · Start Jan 2002 · Primary completion Feb 2009
Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel · For: Breast Cancer
Sites: Neu-Isenburg, Germany
- Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style InterventionPivotal-lookingStatus unknown
Philip HeppAcademic, hospital or other
NCT00847444 · 3,547 participants (planned) · Start Feb 2009 · Primary completion Sep 2011
Drug: Drug-based intervention · For: Breast Cancer
Sites: Düsseldorf, Germany
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabPivotal-lookingTerminated
NSABP Foundation IncResearch network
NCT00625898 · 3,509 participants · Start Apr 2008 · Primary completion Jun 2013
Drug: Docetaxel; Trastuzumab and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 649 sites in all
- Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast CancerPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT01049425 · 3,198 participants · Start Feb 5, 2009 · Primary completion Mar 1, 2017
Drug: Epirubicin; Cyclophosphamide and 3 more · For: Primary Breast Cancer; Her2 Non-overexpressing
Sites: Mönchengladbach, Germany
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT00054587 · 3,010 participants · Start Jun 2001 · Primary completion Jun 2009
Drug: Trastuzumab; Cyclophosphamide and 3 more · For: Breast Cancer
Sites: Angers, France; Annecy, France; Bordeaux, France · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myelosuppression726
- nausea553
- white blood cell count decreased493
- alopecia459
- vomiting419
- febrile neutropenia371
- pyrexia339
- asthenia326
- neutropenia278
- hepatic function abnormal274
- neutrophil count decreased272
- off label use235
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 33 |
| 2005 | 14 |
| 2006 | 20 |
| 2007 | 62 |
| 2008 | 67 |
| 2009 | 50 |
| 2010 | 137 |
| 2011 | 269 |
| 2012 | 334 |
| 2013 | 135 |
| 2014 | 120 |
| 2015 | 185 |
| 2016 | 169 |
| 2017 | 153 |
| 2018 | 361 |
| 2019 | 337 |
| 2020 | 290 |
| 2021 | 388 |
| 2022 | 709 |
| 2023 | 722 |
| 2024 | 838 |
| 2025 | 636 |
| 2026 | 469 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Ellence* (Epirubicin HCL*) · HCPCS J9178
2024 spending
$4K
Beneficiaries
27
75 claims
Per beneficiary
$146
2024 ASP limit $1.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,129 |
| 2021 | $8,402 |
| 2022 | $8,612 |
| 2023 | $5,569 |
| 2024 | $3,936 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neoadjuvant therapy with gemcitabine in breast cancer.
Schneeweiss A, Bastert G, Huober J, et al. · Oncology (Williston Park) 2004 · Clinical Trial, Clinical Trial, Phase I
- Epirubicin in advanced gastrointestinal (GI) cancer.
Wils JA · Onkologie 1986 · Clinical Trial
- Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
Trudeau ME · Oncology (Williston Park) 2001 · Clinical Trial, Randomized Controlled Trial
- Chemotherapy for advanced gastric cancer.
Wagner AD, Grothe W, Behl S, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Long-term efficacy and toxicity of the FEC100 regimen.
Bonneterre JM · Oncology (Williston Park) 2004 · Clinical Trial, Randomized Controlled Trial
- A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T, Quhal F, Kawada T, et al. · Eur Urol Focus 2023 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.